Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any 
transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement 
issued today indicating that Opiant Pharmaceuticals and Hikma have entered into 
a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in 
Europe and the UK.    

About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI: 
549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for millions of people 
around the world. For more than 40 years, we've been creating high-quality 
medicines and making them accessible to the people who need them. Headquartered 
in the UK, we are a global company with a local presence across the United 
States (US), the Middle East and North Africa (MENA) and Europe, and we use our 
unique insight and expertise to transform cutting-edge science into innovative 
solutions that transform people's lives. We're committed to our customers, and 
the people they care for, and by thinking creatively and acting practically, we 
provide them with a broad range of branded and non-branded generic medicines. 
Together, our 8,700 colleagues are helping to shape a healthier world that 
enriches all our communities. We are a leading licensing partner, and through 
our venture capital arm, are helping bring innovative health technologies to 
people around the world. For more information, please visit: www.hikma.com 

(C) 2022 Hikma Pharmaceuticals PLC. All rights reserved.

Source: Hikma Pharmaceuticals PLC